

Area	Treatment
Headquarter	Berlin, DE
Countries of operation	Germany
Founding year	2019
Status	Prototype

Incubator programme P4 Precision Medicine Accelerator, London

Awards Novartis Digital Healthprize

Revenue (last yr) N/A

Funds raised £80k


Currently raising: £500k

Summary

Remissio is a Berlin-based start-up that uses artificial intelligence to develop combination therapy for cancer using artificial intelligence. We are the first company that used AI to model adverse effects of immunotherapies in cancer patients using our deep understanding of gene and protein networks. Our software platform is designed to predict the right combination of chemo and immunotherapy for cancer patients and develop new therapeutic combinations. We are backed by P4 Precision Medicine Accelerator in the UK and Novartis.

USE OF FUNDS

■ Software development ■ Sales



Interested? Get in touch

✉ greg@clab.ventures
www.remission.co